Appointment of Non-Executive Independent Directors Mr. Anshu Agarwal and Mrs. Sonal Desai.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals' board, at its meeting on July 30, 2025, appointed Mr. Anshu Agarwal (Chartered Accountant, Audit Associate at Fust Charles LLP) and Ms. Sonal Desai (Company Secretary with corporate governance expertise) as Additional Non-Executive Independent Directors for a five-year term, subject to shareholder approval. Both are confirmed independent of the promoter group and not debarred by SEBI. The board also approved the unaudited Q1 FY26 results, showing standalone net sales of Rs. 11,940.29 lakhs (up ~54% YoY from Rs. 7,753.58 lakhs) and profit after tax of Rs. 676.58 lakhs (up ~64% YoY from Rs. 412.99 lakhs). EPS for the quarter stood at Rs. 14.33 versus Rs. 8.79 in Q1 FY25. The statutory auditors R.H. Nisar & Co. issued unmodified limited review reports on both standalone and consolidated results.
Strong top-line and bottom-line growth in Q1 FY26 is positive for shareholders, while the addition of two independent directors (one a chartered accountant, one a company secretary) strengthens board governance and financial oversight. This is a routine governance and results update with no negative signals.